
Ask a doctor about a prescription for IRBESARTAN TARBIS FARMA 150 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Irbesartan Tarbis Farma 75 mg film-coated tablets EFG
Irbesartan Tarbis Farma 150 mg film-coated tablets EFG
Irbesartan Tarbis Farma 300 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Irbesartan belongs to a group of medicines called angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that constricts blood vessels, leading to an increase in blood pressure.
Irbesartan prevents angiotensin-II from binding to its receptors, relaxing blood vessels and lowering blood pressure. Irbesartan slows the progression of kidney disease in patients with high blood pressure and type 2 diabetes.
Irbesartan is used in adult patients:
Do not take Irbesartan Tarbis Farma
Warnings and precautions
Talk to your doctor before starting to take irbesartan and if any of the following apply to you:
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Irbesartan Tarbis Farma”.
Talk to your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking irbesartan. Your doctor will decide whether to continue treatment. Do not stop taking irbesartan on your own.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor. It is not recommended to take irbesartan at the start of pregnancy (first 3 months), and in any case, it should not be taken after the third month of pregnancy, as it may cause serious harm to your baby (see section “Pregnancy”).
Children and adolescents
This medicine should not be used in children and adolescents, as the safety and efficacy have not been fully established.
Taking Irbesartan Tarbis Farma with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Your doctor may need to modify your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Irbesartan Tarbis Farma” and “Warnings and precautions”).
You may need to have blood tests if you are taking:
If you are using a type of pain reliever known as non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.
Taking Irbesartan Tarbis Farma with food and drink
Irbesartan Tarbis Farma can be taken with or without food.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will advise you to stop taking irbesartan before you become pregnant or as soon as you find out you are pregnant and recommend an alternative blood pressure-lowering medicine. It is not recommended to take irbesartan at the start of pregnancy and in any case, it should not be taken after the third month of pregnancy, as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. It is not recommended to take irbesartan during breastfeeding, as it is not known whether irbesartan passes into breast milk. Your doctor may decide to prescribe a different treatment that is more suitable if you want to breastfeed, especially for newborns or premature babies.
Driving and using machines
It is unlikely that irbesartan will affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, talk to your doctor before driving or using machines.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Method of administration
Irbesartan Tarbis Farma is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). Irbesartan Tarbis Farma can be taken with or without food. Try to take your daily dose at the same time each day. It is important to continue taking this medicine until your doctor tells you to stop.
The usual dose is 150 mg once daily. Depending on the response to blood pressure, this dose may be increased to 300 mg once daily.
In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney disease is 300 mg once daily.
Your doctor may advise a lower dose, especially at the start of treatment, in certain patients, such as those on hemodialysisor over 75 years of age.
The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.
Use in children and adolescents
Irbesartan Tarbis Farma should not be given to children under 18 years of age. If a child swallows several tablets, contact your doctor immediately.
If you take more Irbesartan Tarbis Farma than you should
If you accidentally take too many tablets, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Irbesartan Tarbis Farma
If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
However, some of these side effects can be serious and may require medical attention.
As with similar medicines, in rare cases, the following have been reported for patients treated with irbesartan: allergic skin reactions (rash, urticaria), as well as localized swelling in the face, lips, and/or tongue. If you think you may have a reaction of this type or experience difficulty breathing, stop taking Irbesartan Tarbis Farma and seek immediate medical attention.
The following side effects are grouped by frequency:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
The following side effects were reported in clinical trials in patients treated with irbesartan:
Since the marketing of irbesartan, the following side effects have been reported. The frequency of these side effects is not known: feeling of spinning, headache, altered taste, ringing in the ears, muscle cramps, muscle and joint pain, decreased number of red blood cells (anemia - symptoms can include tiredness, headaches, difficulty breathing when exercising, dizziness, and paleness), reduced number of platelets, abnormal liver function, high potassium levels in the blood, impaired kidney function, inflammation of small blood vessels, mainly in the skin area (a condition known as leukocytoclastic vasculitis), severe allergic reactions (anaphylactic shock), and low blood sugar levels. There have also been rare cases of jaundice (yellowing of the skin and/or whites of the eyes).
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Irbesartan Tarbis Farma
The active substance is irbesartan.
Each film-coated tablet contains 75 mg of irbesartan.
Each film-coated tablet contains 150 mg of irbesartan.
Each film-coated tablet contains 300 mg of irbesartan.
The other ingredients are
Core:microcrystalline cellulose, sodium croscarmellose, povidone (Kollidon 30), colloidal silicon dioxide, calcium stearate.
Coating:hypromellose, titanium dioxide, talc (E553b).
Appearance and packaging
Irbesartan Tarbis Farma 75 mg film-coated tablets EFG
White to off-white, capsule-shaped, biconvex film-coated tablets (approximately 9.10 mm x 4.60 mm), engraved with "158" on one side and "H" on the other.
Irbesartan Tarbis Farma 150 mg film-coated tablets EFG
White to off-white, capsule-shaped, biconvex film-coated tablets (approximately 11.59 mm x 5.58 mm), engraved with "159" on one side and "H" on the other.
Irbesartan Tarbis Farma 300 mg film-coated tablets EFG
White to off-white, capsule-shaped, biconvex film-coated tablets (approximately 15.12 mm x 6.58 mm), engraved with "160" on one side and "H" on the other.
Irbesartan Tarbis Farma film-coated tablets are available in blisters of 28, 30, 56, 90, 98, and 500 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorization holder
Tarbis Farma S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Spain
Manufacturer
Amarox Pharma B.V.
Rouboslaan 32
Voorschoten, 2252TR
Netherlands
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany: Irbesartan Amarox 75 mg/150 mg/300 mg film-coated tablets
Netherlands: Irbesartan Amarox 75 mg/150 mg/300 mg film-coated tablets
Spain: Irbesartán Tarbis Farma 75 mg/150 mg/300 mg film-coated tablets EFG
Date of last revision of this leaflet: December 2024
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of IRBESARTAN TARBIS FARMA 150 mg FILM-COATED TABLETS in December, 2025 is around 7.74 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IRBESARTAN TARBIS FARMA 150 mg FILM-COATED TABLETS – subject to medical assessment and local rules.